From the Guidelines
Revafenacin should not be considered a first-line treatment for overactive bladder (OAB) in adults, as oral anti-muscarinics such as darifenacin, fesoterodine, oxybutynin, solifenacin, tolterodine, or trospium are recommended as second-line therapy 1. When managing OAB, it is essential to consider the potential benefits and side effects of treatment options.
- Oral anti-muscarinics, including those listed above, can reduce symptoms but are commonly associated with non-life-threatening side effects such as dry mouth, constipation, dry eyes, blurred vision, dyspepsia, UTI, urinary retention, and impaired cognitive function 1.
- Patients with more severe symptoms may experience greater symptom reductions, while those with relatively low baseline symptom levels are more likely to achieve complete symptom relief 1.
- The choice of medication should be based on individual patient factors, such as symptom severity, medical history, and potential side effects.
- As revafenacin is not mentioned in the provided guideline, its use in OAB treatment cannot be recommended based on this evidence 1.
- In clinical practice, the treatment of OAB should prioritize medications with established efficacy and safety profiles, such as the oral anti-muscarinics listed in the guideline 1.
From the FDA Drug Label
The FDA drug label does not answer the question.
From the Research
Revafenacin Information
- There are no research papers to assist in answering this question about Revafenacin as the provided studies do not mention Revafenacin.
- The studies provided discuss other medications such as solifenacin, mirabegron, darifenacin, tolterodine, oxybutynin, trospium, and fesoterodine, which are used to treat overactive bladder syndrome (OAB) 2, 3, 4, 5, 6.
- These studies compare the efficacy and tolerability of these medications in treating OAB symptoms such as micturition frequency, incontinence, and urgency 3, 4, 6.
- Solifenacin is found to be efficacious and well-tolerated in treating OAB symptoms in elderly subjects 5 and is considered a drug of choice when considering efficacy, tolerability, and cost 6.